These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 33382567)

  • 21. Treatment-resistant depression: problematic illness or a problem in our approach?
    Malhi GS; Das P; Mannie Z; Irwin L
    Br J Psychiatry; 2019 Jan; 214(1):1-3. PubMed ID: 30565539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Nasal Spray for Treatment-Resistant Depression.
    Aschenbrenner DS
    Am J Nurs; 2019 Jul; 119(7):22. PubMed ID: 31232770
    [No Abstract]   [Full Text] [Related]  

  • 23. Improving the care of patients who have treatment-resistant depression: the promise of the PCORnet Mood Network.
    Nierenberg AA; Sylvia L; Doederlein A; Edgman-Levitan S; Muskin A; Jewell L; Walker M; Goodman D; Farahbakhsh M; Hearing C; Tovey R; Deckersbach T
    J Clin Psychiatry; 2015 Apr; 76(4):e528-30. PubMed ID: 25919850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Esketamine/ketamine for treatment-resistant depression.
    Lacerda ALT
    Braz J Psychiatry; 2020; 42(6):579-580. PubMed ID: 32401866
    [No Abstract]   [Full Text] [Related]  

  • 25. N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression.
    Carvalho AF; Macêdo DS; Goulia P; Hyphantis TN
    J Clin Psychopharmacol; 2013 Oct; 33(5):719-20. PubMed ID: 23899640
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
    De Gioannis A; De Leo D
    Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289
    [No Abstract]   [Full Text] [Related]  

  • 27. Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.
    McIntyre RS
    Am J Psychiatry; 2021 Dec; 178(12):1130-1132. PubMed ID: 34855455
    [No Abstract]   [Full Text] [Related]  

  • 28. Antidepressant-Resistant Depression in Patients With Comorbid Subclinical Hypothyroidism or High-Normal TSH Levels.
    Cohen BM; Sommer BR; Vuckovic A
    Am J Psychiatry; 2018 Jul; 175(7):598-604. PubMed ID: 29961367
    [No Abstract]   [Full Text] [Related]  

  • 29. Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
    López-Díaz Á; Murillo-Izquierdo M; Moreno-Mellado E
    Br J Psychiatry; 2019 Aug; 215(2):447-448. PubMed ID: 31030677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short - Term Ketamine Administration in Treatment - Resistant Depression: Focus on Cardiovascular Safety.
    Del Sant L; Sarin LM; de Jesus Mari J
    Psychiatr Danub; 2020; 32(2):219-220. PubMed ID: 32796789
    [No Abstract]   [Full Text] [Related]  

  • 31. [Off-label ketamine treatment for treatment-resistant depression: win-win?].
    Smith-Apeldoorn SY; Veraart JKE; Schoevers RA
    Tijdschr Psychiatr; 2019; 61(8):516-518. PubMed ID: 31512733
    [No Abstract]   [Full Text] [Related]  

  • 32. [Fatty acids in treatment and prevention of depression].
    Wilczyńska A
    Psychiatr Pol; 2013; 47(4):657-66. PubMed ID: 24946472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Treatment of Major Depressive Disorder With Add-On Buprenorphine in a Patient With Previous Nonresponse to Standard Antidepressants.
    Elsayed M; Gahr M; Connemann BJ; Schönfeldt-Lecuona C
    Prim Care Companion CNS Disord; 2017 Sep; 19(5):. PubMed ID: 28972704
    [No Abstract]   [Full Text] [Related]  

  • 35. Managing patients who are ultra-rapid metabolisers of antidepressant medications.
    Parker G
    Australas Psychiatry; 2016 Aug; 24(4):374-5. PubMed ID: 27130726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 37. Investigational drugs in recent clinical trials for treatment-resistant depression.
    Garay RP; Zarate CA; Charpeaud T; Citrome L; Correll CU; Hameg A; Llorca PM
    Expert Rev Neurother; 2017 Jun; 17(6):593-609. PubMed ID: 28092469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frontiers in Therapy of Treatment-Resistant-Depression: A Future Role of Ketamine?
    Kwak S; Tiller D; Tucker P
    J Okla State Med Assoc; 2015 Mar; 108(3):88-9. PubMed ID: 26242015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression - report of two cases.
    Schmidt FM; Kirkby KC; Himmerich H
    Psychiatr Danub; 2014 Sep; 26(3):288-90. PubMed ID: 25191779
    [No Abstract]   [Full Text] [Related]  

  • 40. The Future of Ketamine in the Treatment of Teen Depression.
    Parikh T; Walkup JT
    Am J Psychiatry; 2021 Apr; 178(4):288-289. PubMed ID: 33789452
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.